Co-Diagnostics wins increased US patent protection for its CoPrimer technology used in its coronavirus test kit

Co-Diagnostics Inc (NASDAQ:CODX) announced Thursday the US Patent and Trademark Office has granted increased patent protection for the company’s novel CoPrimer technology used in its coronavirus (COVID-19) test kit and other molecular diagnostic tests. The Salt Lake City-based company said the new patent further validates the uniqueness of the CoPrimer molecule and provides even more comprehensive protection for all of its potential applications. The original patent covered certain applications of the CoPrimer molecule - which has been shown to enhance the output of polymerase chain reaction (PCR) molecular diagnostic tests by dramatically minimizing false-positive test results - and its use in PCR, but not the molecule itself.  READ: Co-Diagnostics delivers $12.6 million profit in 2Q as demand for COVID-19 test kits propel stellar results The additional patent covers the physical structure of the CoPrimer molecule, with more broad claims and including all configurations of a molecule with such a structure. CoPrimer technology is the platform used in the company's flagship COVID-19 testing kits, which have been deployed throughout the world and across the US. The technology has also been licensed for certain applications by LGC, Biosearch Technologies, an international leader in the extended life sciences sector, whose footprint covers over 200 countries. "Receiving this additional patent emphasizes the uniqueness of our CoPrimer technology,” Co-Diagnostics CEO Dwight Egan said in a statement. “The beneficial advantages of CoPrimers in test design and performance are already being realized by laboratories across the country and rest of the world, particularly in the battle against the coronavirus pandemic, which has propelled the company to significant revenues and profitability.” Egan noted that the CoPrimer-based Logix Smart COVID-19 test kit has been authorized for use as an in vitro diagnostic by regulatory authorities in the US, Europe, Mexico, India, Australia, and other countries after validations confirming its performance and quality have been performed by or presented to the regulatory bodies in those regions.  “In addition to infectious disease diagnostics, this technology platform also serves as the foundation for Co-Diagnostics' other verticals, including our growing mosquito abatement/vector control vertical, AgBio, liquid biopsy technology, and next-gen sequencing applications,” Egan added. Contact the author: patrick@proactiveinvestors.com Follow him on Twitter @PatrickMGraham